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Abstract
Background: Chronic kidney disease (CKD), cognitive impairment and depression share common risk factors.
Previous studies did not investigate the possible association between kidney function and cognitive and mood
disorders in older persons in a broad range of kidney function. The present study explored associations between
kidney function, cognition and mood in outpatients of 75 years and over.
Methods: Baseline data of 2252 participants of the SCOPE study, an international multicenter cohort observational
study,were used in which community-dwelling persons of 75 years and over were enrolled to screen for CKD
Kidney function was estimated with the BIS1-eGFR equation, cognition was assessed with the Mini-Mental State
Examination (MMSE) and mood with the Geriatric Depression Scale 15 items (GDS-15). Characteristics were
compared across stages of CKD. Mean eGFR values were also compared across categories of MMSE (< 24, 24–26,
≥27) and between groups with high and low score on the GDS-15 (> 5/≤5).
Results: In total, 63% of the population had an eGFR < 60 mL/min. In advanced stages of CKD, participants were
older and more often men than in earlier stages (p < 0.001). Cardiovascular diseases and diabetes mellitus were
more often found in those in advanced stages of CKD (p < 0.001), and also cumulative comorbidity scores were
higher than in those in earlier stages (p < 0.001). Median MMSE was 29 in CKD stage 1–2 and 3, and 30 in CKD
stage 4, whereas median GDS-15 score was 2 in all stages of CKD. Mean values of eGFR did not differ across
categories of MMSE or between groups with high and low score on the GDS-15. Stratification for albuminuria did
not change these results.
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Conclusions: Older persons in more advanced stages of CKD did not have lower cognitive scores or higher rates of
depressive symptoms than older persons in earlier stages. Future longitudinal studies might give information on
the possible effect of kidney function on cognition and mood in late life.
Trial registration: This study was registered prospectively on 25th February 2016 at clinicaltrials.gov (NCT02691546).
Keywords: Chronic kidney disease, Estimated glomerular filtration rate, Cognition, Cognitive impairment, Mood,
Depressive symptoms, Older persons
Background
The prevalence of chronic kidney disease (CKD), cogni-
tive impairment and cardiovascular conditions is grow-
ing as result of the aging population [1–3]. CKD,
cognitive impairment and mood disorders can share
common risk factors, such as hypertension and diabetes
mellitus [1, 2, 4, 5]. However, whether a decreased kid-
ney function is associated with cognitive and mood dis-
orders in the oldest old is not completely clear.
One of the potential mechanisms underlying the inter-
action between the kidney and the brain may include the
presence of small vessel disease [6]. Persons with CKD
have a higher burden of traditional vascular risk factors
such as hypertension, diabetes mellitus and dyslipidae-
mia which are related to small vessel disease in the kid-
ney [6, 7]. The same risk factors are also associated with
cerebral white matter lesions, microbleeds, lacunar in-
farcts and subcortical atrophy which are markers of
cerebral small vessel disease increasing the risk of stroke,
cognitive decline and dementia [6, 8–11]. Moreover, the
presence of small vessel disease may also underlie the as-
sociation between CKD and depressive symptoms as re-
sult of a disruption of brain structures and connecting
pathways in mood regulation [12]. Both cognition and
mood may also be influenced by metabolic dysregulation
and direct effects of lower glomerular filtration rate
(GFR) [13–15].
Previous studies suggest that CKD and cognitive im-
pairment might be correlated [16]. However, most stud-
ies did not focus on older patients in a broad range of
GFR. In addition, in people in all stages of CKD, it was
found that the prevalence of depressive symptoms
ranged from 7 to 50% and depressive symptoms were
more frequent in people in advanced stages of CKD than
in people in earlier stages [17]. Nonetheless, most study
populations were relatively small and studies did not
focus on older persons. Therefore, the relationship be-
tween kidney function, cognition and mood in late life
remains undetermined.
Since the identification of modifiable risk factors of
cognitive and functional decline such as CKD is relevant,
this study aimed to investigate the possible association
between kidney function, cognition and mood in outpa-
tients aged 75 years and over. We hypothesized that
cognitive impairment and depressive symptoms would
be more prevalent in advanced stages of CKD than in
earlier stages and that persons with cognitive impair-
ment and depressive symptoms would have lower levels
of estimated GFR (eGFR) than persons without. Results
of this study might provide important information in
addition to known risk factors of adverse outcomes in
persons with poor kidney function, cognitive impairment
and depression. These older persons might then benefit
from improved therapeutic strategies when visiting their
nephrologist, geriatrician or psychologist.
Methods
The present study was performed within the framework
of the Screening for Chronic Kidney Disease among
Older People across Europe (SCOPE) study. The SCOPE
study (European Grant Agreement no. 436849), is a
multicenter 2-year prospective cohort study involving
patients older than 75 years attending outpatient services
in participating institutions in Austria, Germany, Israel,
Italy, The Netherlands, Poland and Spain. Methods of
the SCOPE study have been extensively described else-
where [18]. The primary objective of the SCOPE study
was to investigate the currently available screening
methods to identify community-dwelling older patients
at risk of kidney disease. Patients with end-stage renal
disease or dialysis, a history of solid organ or bone mar-
row transplantation, an active malignancy or metastatic
cancer within 24 months prior to the visit, a life expect-
ancy of less than 6 months, a severe cognitive impair-
ment or patients unwilling to provide consent were
ineligible for the SCOPE study. Participants were re-
quested to sign a written informed consent before enter-
ing the study. The study protocol was approved by
ethics committees at all participating institutions, and
complies with the Declaration of Helsinki and Good
Clinical Practice Guidelines. Only baseline data are used
in the present study. Overall, 2461 participants were ini-
tially enrolled in the study.
Kidney function
Serum creatinine (Isotope-Dilution Mass Spectrometry
traceable) and albumin-to-creatinine ratio (ACR) were
measured at local level by standard methods. Creatinine-
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based eGFR was calculated in mL/min/1.73m2 using the
Berlin Initiative Study 1 (BIS1) equation [19]: 3736 × cre-
atinine-0.87 × age-0.95 × 0.82 (if woman).
The prevalence of stages of CKD was obtained using the
Kidney Disease Improving Global Outcomes (KDIGO)
guidelines [20]: eGFR ≥60, stage 1–2; 59.9–45, stage 3a;
44.9–30, stage 3b; and 15–30mL/min/1.73m2, stage 4.
Albuminuria was defined as a urine ACR ≥30mg/g (≥3
mg/mmol) [20].
Cognition
The cognitive functions were measured by the Mini-Mental
State Examination (MMSE) [21]. The MMSE is the most
commonly administered psychometric screening tool of cog-
nitive functioning and available and validated in all languages
of participating countries. The score ranges from 0 to 30
points, whereas a score < 24 is frequently implemented as the
cut-off value for abnormal and indicative of cognitive impair-
ment [22]. A meta-analysis of the accuracy of the MMSE in
the detection of dementia and mild cognitive impairment
showed a pooled sensitivity and specificity of 71.1 and 95.6%
respectively in mixed specialist hospital settings [23]. A
MMSE score of < 27 might identify those with a greater risk
of cognitive dysfunction, especially in highly educated per-
sons [24]. Therefore, in this study, we defined 3 categories
based on the MMSE score: ≥ 27, 24–26 and < 24.
Mood
The 15-item Geriatric Depression Scale-Short Form
(GDS), available and validated in all languages of partici-
pating countries, was used to investigate depressive
symptoms [25]. It focusses on functional and mood
symptoms of depression. The score ranges from 0 to 15
points, with higher scores indicating more depressive
symptomatology. The cut-off score most often used for
this GDS version is 5 or 6 [26]. A recent systematic re-
view and meta-analysis showed a pooled sensitivity and
specificity of 86 and 79%, respectively to detect depres-
sion in older persons [27]. In this study, a score > 5 was
seen as suggestive of depressive symptoms [25].
Other variables
Demographic data and socioeconomic status were
documented. Information on alcohol use, smoking
status, medical history and use of medication was col-
lected and the cumulative illness rating scale for geri-
atrics (CIRS-G) was calculated in order to score the
comorbidity burden by rating the severity of medical
problems affecting various organ systems [28]. During
the study visit, a comprehensive geriatric assessment
(CGA) was performed including also information on
basic activities of daily living (ADL) and instrumental
ADL (IADL) [29, 30].
Statistical analysis
Descriptive statistics were expressed as percentage for
categorical variables and median and interquartile ranges
(IQR) for continuous non-normally distributed variables.
First, characteristics were compared across stages of
CKD using the Chi square test and Kruskal Wallis test.
Second, the correlation between age, MMSE and GDS
was explored using the Spearman’s correlation test.
Third, mean eGFR values were compared across cat-
egories of cognition (MMSE< 24, MMSE 24–26,
MMSE≥27) using analysis of variance (ANOVA) in the
total population and stratified for the presence of albu-
minuria. Then, mean eGFR values were also compared
between participants with low and high score and GDS
(score ≤ 5 and > 5) in the total population and stratified
for the presence of albuminuria. A p-value of < 0.05 was
considered statistically significant.
Results
Overall, 2461 participants were initially enrolled in the
SCOPE study. Of them, 209 participants had missing
data on serum creatinine, MMSE and/or GDS leaving a
final sample of 2252 participants to be included in the
present study. Baseline characteristics are shown in
Table 1. Median age was 79.5 years (IQR 77.1–82.9),
55.7% were women and 24.5% were living alone. The
majority of the population had hypertension (76.8%),
25.1% had diabetes mellitus, 17.2% had a history of ma-
lignancy and 16.6% had congestive heart failure. About
9% had a history of transient ischemic attack and 5.8%
have had a stroke. The median total score on the CIRS-
G was 8 (IQR 5–11). Only 0.6% of the participants had
an eGFR ≥90mL/min/1.73m2, 36.2% were classified as
CKD stage 2, 38.3% had CKD stage 3A, 18.6% had CKD
stage 3B and 6.3% had CKD stage 4. In 26.7% of the
study population, albuminuria was present. Median
score on the MMSE was 29 (IQR 27–30), 7.1% of the
participants had a MMSE score < 24. Median score on
the GDS was 2 (IQR 1–4), 14% of the participants had a
GDS score > 5.
Characteristics stratified for stages of CKD (stage 1–2
merged) are presented in Table 2. In advanced stages of
CKD, participants were older, more often men and
former smokers and had fewer years of education than
in earlier stages. Comorbidities such as cardiovascular
diseases (hypertension, atrial fibrillation, heart failure),
diabetes mellitus and history of malignancy were more
often found in those in advanced stages of CKD and the
CIRS-G total score and severity index were higher than
in those in earlier stages. In participants with CKD stage
1–2, 3a and 3b, median MMSE score was 29 (IQR 27–
30), whereas median MMSE score in participants with
CKD stage 4 was slightly higher with a median value of
30 (IQR 28–30). The proportion of participants with an
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MMSE score < 24 did not differ across stages of CKD,
with a prevalence of 6.4% (stage 1–2), 7.7% (stage 3A),
9.3% (stage 3B) and 5% (stage 4). Median score on the
GDS was the same in all stages of CKD, namely 2 (IQR
1–4). A GDS score > 5 was found in 13, 15, 14.1 and
14.2% of the participants in each stage of CKD, respect-
ively. A correlation was found between age and MMSE
score (Spearman’s rho − 0.229, p < 0.001) and age and
GDS score (Spearman’s rho 0.076, p < 0.001).
Figure 1a shows mean values of eGFR across prede-
fined categories of MMSE. One hundred and fifty nine
participants had a MMSE score < 24, 309 had a MMSE
score of 24–26 and 1784 participants had a MMSE
score ≥ 27. Mean eGFR values did not differ across cat-
egories; mean values and 95% CI were 53.5 (51.1–55.8),
55 (53.4–56.5) and 54.7 (53.9–55.4) mL/min/1.73m2, re-
spectively. Mean values of eGFR did not differ between
participants with a low (n = 1936) and high score (n =
316) on the GDS; mean values and 95% CI were 54.7
(54–55.3) and 54.3 (52.6–55.9) mL/min/1.73m2, respect-
ively. Results are shown in Fig. 1b.
In Fig. 2a mean values of eGFR in participants with
and without albuminuria are shown across categories of
MMSE. In participants with albuminuria, 45 participants
had a MMSE score < 24, 86 had a MMSE score of 24–26
and 470 participants scored ≥27. Mean values of eGFR
did not differ across categories; mean values and 95% CI
were 47.1 (42–52.3), 47.1 (43.6–50.5) and 45.2 (43.7–
46.8) mL/min/1.73m2, respectively. In participants with-
out albuminuria, the number of participants in the same
categories were 114, 223 and 1314, respectively. Mean
eGFR values did not differ across categories; mean
values and 95% CI were 56 (53.5–58.4), 58 (56.5–59.5)
and 58 (57.2–58.7) mL/min/1.73m2, respectively. Fig-
ure 2b shows mean values of eGFR in participants with
and without albuminuria in groups with a low and high
score on the GDS. In participants with albuminuria,
mean values of eGFR did not differ between participants
with a low (n = 517) and high score (n = 84); mean values
and 95% CI were 45.5 (44.1–47) and 46.4 (42.7–50.1)
mL/min/1.73m2. In participants without albuminuria,
mean values of eGFR did also not differ between groups.
Mean eGFR was 58mL/min/1.73m2 (95%CI 57.3–58.7)
in participants with a low score (n = 1419) and 57.1 mL/
min/1.73m2 (95% CI 55.4–58.8) in participants with a
high score on the GDS (n = 232).
Discussion
Within the framework of the SCOPE study, a large ob-
servational cohort including persons aged 75 years and
older, we found that early or advanced kidney disease
seemed to have no negative influence on cognition or
mood in late life. Also, no differences in kidney function
were observed in participants with and without cognitive
impairment and in those with and without depressive
symptoms. The presence of albuminuria did not influ-
ence our results.
We found that participants in progressively later stages
of CKD were more likely to have risk factors for (cere-
bral) small vessel disease, such as hypertension and dia-
betes mellitus, than participants in earlier stages [6].
Table 1 Baseline characteristics (n = 2252)
Age, years 79.5 (77.1–82.9)
Women, % 55.7
Living alone, % 24.5
Education, years 11 (8–15)
Smoking status
Current smoker, % 4.4
Former smoker, % 39.5
Alcohol ≥1 unit a day, % 25.8
BMI, kg/m2 27.3 (24.7–30.4)
ADL-independent, % 95.2
iADL-independent, n % 56
MMSE, score 29 (27–30)
MMSE < 24, % 7.1
GDS, score 2 (1–4)
GDS > 5, % 14
Hypertension, % 76.8
Diabetes mellitus, % 25.1
TIA, % 8.7
Stroke, % 5.8
Atrial fibrillation, % 15.3
COPD, % 11.8
Cancer, % 17.2
CHF, % 16.6
Vascular disease, % 12.6
CIRS-G, total score 8 (5–11)
CIRS-G, severity index 1.5 (1.2–1.8)
eGFR-BIS, mL/min/1.73 m2 55.6 (45.1–64.4)
90 or more, % 0.6
60–89.9, % 36.2
45–59.9, % 38.3
30–44.9, % 18.6
30 or less, % 6.3
ACR, mg/g 11.2 (33.1–3.4)
Albuminuria, % 26.7
Values are expressed as percentage or median (IQR)
Abbreviations: BMI Body Mass Index, (i) ADL (instrumental) Activities of Daily
Living, MMSE Mini–Mental State Examination, GDS Geriatric Depression Scale,
TIA Transient Ischemic Attack, COPD Chronic Obstructive Pulmonary Disease,
CHF Congestive Heart Failure, CIRS-G Cumulative Illness Rating Scale for
Geriatrics, eGFR-BIS Estimated Glomerular Filtration Rate, ACR
Albumin-to-Creatinine Ratio
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Also other conditions closely linked to (cerebral) small
vessel disease were more prevalent in those in advanced
stages of CKD than in those in early stages, such as atrial
fibrillation, congestive heart failure and history of stroke
[31–33]. The presence of these risk factors is suggested
to mediate associations between the kidney and the
brain [6], however, we were not able to confirm our
prior hypothesis. Previous cross-sectional studies investi-
gated the association between CKD and cognitive im-
pairment in older persons. Most studies investigated this
topic in specific populations, such as women with coron-
ary artery disease [34] or only men [35]. In a large
sample in the United States of America, it was found
that lower levels of kidney function were associated with
an increased prevalence of cognitive impairment,
assessed with a six-item cognitive screening [36]. In this
study, kidney function was assessed by the Modification
of Diet in Renal Disease Study (MDRD) equation, an
equation that is less reliable than the BIS1 equation in
older persons [19], therefore, it is possible that the
method used to assess eGFR might have induced bias.
To the best of our knowledge, this is the first cross-
sectional study investigating the possible association be-
tween kidney function and depressive symptoms in a
Table 2 Baseline characteristics across stages of chronic kidney disease (CKD)
Stages of CKD p-
valueStage 1–2 (n = 830) Stage 3A (n = 862) Stage 3B (n = 419) Stage 4 (n = 141)
Age, years 78.6 (76.5–81.1) 79.6 (77.3–83.1) 81 (78.2–85.1) 81 (77.7–84.8) < 0.001
Women, % 61.1 56.8 47.7 40.4 < 0.001
Living alone, % 23.1 23.7 26 32.6 ns
Education, years 12 (8–16) 11.5 (8–15) 10 (8–13) 8 (8–12) < 0.001
Smoking status,
Current smoker, % 5.5 3.6 4.1 3.5 ns
Former smoker, % 35.7 40 44.3 44.9 0.017
Alcohol ≥1 unit a day, % 26.6 24.2 27.2 24.8 ns
BMI, kg/m2 26.7 (24.2–29.6) 27.4 (24.8–30.6) 27.7 (25.3–31.0) 27.7 (24.9–31.4) < 0.001
ADL-independent, % 97.1 95.7 92.1 90.1 < 0.001
iADL-independent, % 66 79.5 72.3 70.2 < 0.001
MMSE, score 29 (27–30) 29 (27–30) 29 (27–30) 30 (28–30) 0.001
MMSE < 24, % 6.4 7.7 9.3 5 ns*
GDS, score 2 (1–4) 2 (1–4) 2 (1–4) 2 (1–4) ns
GDS > 5, % 13 15 14.1 14.2 ns
Hypertension, % 66.3 77.6 89.3 96.5 < 0.001
Diabetes mellitus, % 19.3 22.6 38.2 36.2 < 0.001
TIA, % 8 8.4 11.2 7.8 ns
Stroke, % 4.3 5.7 7.9 9.2 0.023
Atrial fibrillation, % 9.3 16.6 22 22.7 < 0.001
COPD, % 8.9 11.3 16.7 17.7 < 0.001
Cancer, % 14.2 17.2 20.8 24.8 0.002
CHF, % 8.4 17.9 23.9 34.8 < 0.001
Vascular disease, % 10.8 12.3 16.5 13.5 0.042
CIRS-G, total score 7 (4–10) 7 (5–10) 10 (7–14) 11.5 (8.3–15) < 0.001
CIRS-G, severity index 1.4 (1.2–1.7) 1.5 (1.2–1.8) 1.7 (1.3–1.9) 1.8 (1.5–2) < 0.001
eGFR-BIS, mL/min/1.73 m2 67.2 (63.6–73.1) 53.8 (50.2–56.9) 39.0 (34.9–42.3) 24 (20.5–27.1) < 0.001
ACR, mg/g 8.3 (1.9–18.7) 9.4 (3.3–24.3) 24.5 (7–121.8) 161 (53.7–1006) < 0.001
Albuminuria, % 14 20.8 45.6 81.6 < 0.001
Continuous variables are expressed as median (IQR)
Abbreviations: BMI Body Mass Index, (i) ADL (instrumental) Activities of Daily Living, MMSE Mini–Mental State Examination, GDS Geriatric Depression Scale, TIA
Transient Ischemic Attack, COPD Chronic Obstructive Pulmonary Disease, CHF Congestive Heart Failure, CIRS-G Cumulative Illness Rating Scale for Geriatrics, eGFR-
BIS Estimated Glomerular Filtration Rate, ACR Albumin-to-Creatinine Ratio
*Adjusted for age, sex and education
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large study population of community dwelling persons
in late life within a broad range of eGFR. In a recent
meta-analysis, lower kidney function was associated with
higher prevalence of depression [17]. However, only two
studies investigated persons with a mean age above 70
years [37, 38]. In a Korean population-based cohort
study including almost 1000 participants aged 65 years
and older, it was found that an eGFR < 45mL/min was
associated with poor physical quality of life but not with
mental health [37]. In older patients admitted with
congestive heart failure [38], depression was more preva-
lent among those with than those without severe CKD
(< 30 vs ≥ 30 mL/min). However, since this is a very spe-
cific study population, these results cannot be com-
pletely compared to our results. Both previous studies
used different tools to investigate depressive symptoms
[37, 38]: the Short Form 36 (SF-36) health survey and
the Beck Depression Inventory (BDI), respectively.
Therefore it cannot be excluded that the different
methods used might have affected the reported results.
Fig. 1 Mean eGFR values across categories of MMSE (a) and in participants with low and high score on the GDS (b). Notes: Squares represent
mean values, bars represent 95% CI. Abbreviations: eGFR, estimated glomerular filtration rate; MMSE, mini-mental state examination; GDS, geriatric
depression scale
Fig. 2 Mean eGFR values across categories of MMSE (a) and in participants with low and high score on the GDS (b) stratified for albuminuria.
Notes: Open dots represent mean values in participants with albuminuria, closed dots represent mean values in participants without albuminuria,
bars represent corresponding 95% CI. Albuminuria: n = 45, n = 86, n = 470 from lowest to highest category of MMSE score; participants per
category GDS, n = 517 (low), n = 84 (high). No albuminuria: n = 114, n = 223, n = 1314 from lowest to highest category of MMSE score; participants
per category GDS, n = 1419 (low), n = 232 (high). Abbreviations: eGFR, estimated glomerular filtration rate; MMSE, mini-mental state examination;
GDS, geriatric depression scale
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A possible explanation for our findings could lie in the
selection of our study population. Eligible persons were
community-dwelling, 75 years and older and referred to
the outpatient clinics of participating institutions, which
might have resulted in a ceiling effect. Almost all partici-
pants were under regular medical monitoring at out-
patient services, which might have resulted in a better
control of cardiovascular risk factors. Therefore, the kid-
ney function and its mediators might no longer be re-
lated on the outcomes of interest. One might argue
whether kidney function is relevant for the brain (cogni-
tion and mood) in the outpatient with multimorbidity in
late life or whether all comorbidities in the older out-
patient equally contribute to (disturbances in) cognition
and mood.
Some limitations of the study need to be discussed.
First, the cross sectional design does not allow to investi-
gate causal inferences. Second, persons with relatively
good cognition and mood are more likely to volunteer
to participate in this study with an extensive protocol,
which might have affected our results. Third, persons
with end stage renal disease were not included in this
study. It might be speculated that mood and cognition
are not yet affected in stages 1–4 of CKD due to the
asymptomatic nature of the disease. Fourth, there might
be a survival bias in which individuals with CKD in ad-
vanced stages and possibly cognitive impairment and/or
depressive symptoms already died and therefore were
not included. Fifth, our study did not include a direct
measurement of GFR, however, we used the eGFR-BIS1
equation which is one of the most reliable creatinine-
based equations at older age [19]. Eventually, we used
the MMSE to assess cognition and the GDS-15 to assess
depressive symptoms. We cannot exclude that perform-
ing a complete neuropsychological evaluation or using
other screening tools might have given different results
and might be able to confirm our hypotheses. Ideally,
such a complete neuropsychological evaluation can be
used in future studies.
This study also has strengths. We have studied a large
real-world population of older outpatients in 7 different
countries across Europe, therefore our findings can be
extrapolated to a large population of European citizens.
Second, information on kidney function, cognition and
mood were obtained systematically in all participating
centers, which makes the results highly reliable.
Conclusions
In community-dwelling older persons in more advanced
stages of CKD, cognitive impairment and depressive
symptoms were not more prevalent than in older per-
sons without or in earlier stages of CKD. Kidney func-
tion was comparable in those with and without any signs
of cognitive or mood disorders. The identification of
CKD as modifiable risk factor for cognitive impairment
and depressive symptoms in late life might be relevant
in order to optimize therapeutic strategies. Longitudinal
studies might give additional information on the possible
effect of kidney function on mental health in late life. An
ongoing prospective SCOPE study is now conducted to
investigate effects of CKD progression on these
variables.
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